Enanta Pharmaceuticals | ENTA - Cash And Equivalent


Enanta Pharmaceuticals reported $37.44M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Amgen USD 12.04B 2.91B Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Immunic USD 15.48M 19.65M Dec/2025
Incyte USD 4.02B 435.22M Mar/2026
Insmed USD 510.44M 175.68M Dec/2025
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novavax USD 240.63M 27.39M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026